首届St Gallen国际晚期前列腺癌专家共识荟萃

Recommendation of the St Gallen advanced prostate cancer consesus conference,2015

前列腺癌治疗方面的循证医学证据较多,目前迫切需要形成共识指导临床治疗。2015-03首届国际晚期前列腺癌(advanced prostate cancer,APC)会议在欧洲小镇圣加仑(St Gallen)召开,会议专家委员会基于循证医学证据,对晚期前列腺癌的临床诊疗领域热点问题通过讨论达成共识,并对有分歧的观点作出客观评价。最终的汇总结果刊登于2015-06-28《Annals of Oncology》杂志。本年度专家共识重点内容包括晚期去势敏感性前列腺癌的治疗、寡转移性去势敏感性前列腺癌的治疗、去势抵抗的定义、非转移性(M0期)去势抵抗性前列腺癌(castration resistance prostate cancer,CRPC)的治疗、内分泌治疗、转移性CRPC的治疗策略及治疗次序和前列腺癌的多学科治疗等多个方面。本研究就去势敏感性与去势抵抗性前列腺癌的治疗以及多学科治疗进行阐述,为临床中APC的治疗提供理论指导。

There are more and more evidenced-based medicine of prostate cancer, which is urgent to need to form consensus. In March 2015, the first St Gallen Advanced Prostate Cancer Consensus Conference was held at the town of St Gallen, which was based on the evidence-based medicine and reached a consensus through discussion of the clinical diagnosis and treatment of advanced prostate cancer. In addition, the experts made an objective evaluation of the divergent views. The various recommendations carrying differing degrees of support was available at Annals of Oncology online. During the meeting, the experts discussed the fullowing in details： management of men with castration-naive metastatic prostate cancer, management of men with oligometastatic castration-naive prostate cancer, the definition of castration re sistance, management of men with non-metastatic （M0） CRPC, endocrine manipulations, treatment choice and sequencing for men with metastatic CRPC, multidisciplinary care of men with prostate cancer and so on. In this paper, we focus on the treatment of castration-naive or castration resistance prostate cancer and multidisciplinary treatment and others. This article provides theoretical basis for the treatment of advanced prostate cancer.